These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 23032654

  • 1. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S.
    Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 4. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A, Sire M.
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract] [Full Text] [Related]

  • 8. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.
    J Natl Cancer Inst; 2008 Feb 20; 100(4):282-4. PubMed ID: 18270341
    [No Abstract] [Full Text] [Related]

  • 9. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
    Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T.
    Clin Exp Nephrol; 2012 Apr 20; 16(2):310-5. PubMed ID: 21964704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
    Jonkers IJAM, van Buren M.
    Clin Exp Nephrol; 2009 Aug 20; 13(4):397-401. PubMed ID: 19381758
    [Abstract] [Full Text] [Related]

  • 16. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.
    J Clin Oncol; 2010 May 01; 28(13):2280-5. PubMed ID: 20351323
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.
    J Urol; 2008 Jan 01; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [Abstract] [Full Text] [Related]

  • 20. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M, Haseke N, Schöppler G, Stadler T, Heinemann G, Stief CG.
    Urologe A; 2006 Oct 01; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.